TBL1XR1

Across TCGA pan-cancer cohorts, TBL1XR1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of TBL1XR1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TBL1XR1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TBL1XR1 is over-expressed in tumor.

CCRCC, COAD, and LSCC are the cancer types where TBL1XR1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TBL1XR1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	+0.600	<.001	12	view →
COAD	All	IV	+0.290	<.001	12	view →
LSCC	Male	III,IV	+0.797	<.001	9	view →
LUAD	Male	All	+0.394	<.001	9	view →
HNSC	Male	IV	+0.499	<.001	8	view →
PDAC	Male	All	+0.219	.005	4	view →
OV	All	All	+0.474	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

TBL1XR1–CCRCC

Open the CCRCC breakdown →